This demographic shift is placing immense strain on health and social care systems worldwide, and calls for bold, innovative ...

The White House has confirmed that the trade deal signed with the EU – which includes an overarching tariff rate of 15% on ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' Piqray/Vijoice (alpelisib) and Roche's Itovebi (inavolisib), which are currently ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

This approach, while embedded in clinical guidelines and workflow protocols, does not reflect the underlying biology of ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients ...